42 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake https://www.fool.com/investing/2019/10/28/wall-street-has-given-up-on-these-3-stocks-and-tha.aspx?source=iedfolrf0000001 Oct 28, 2019 - Value investing is all about being willing to buy solid companies when the market throws a sale.
Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales http://www.zacks.com/stock/news/596377/sanofi-sny-q3-earnings-beat-vaccines-chc-units-hurt-sales?cid=CS-ZC-FT-analyst_blog|earnings_article-596377 Oct 31, 2019 - Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.
Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View http://www.zacks.com/stock/news/604652/allergan-agn-meets-q3-earnings-estimates-ups-19-sales-view?cid=CS-ZC-FT-analyst_blog|earnings_article-604652 Nov 05, 2019 - Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength http://www.zacks.com/stock/news/606644/radius-rdus-q3-earnings-beat-estimates-on-tymlos-strength?cid=CS-ZC-FT-analyst_blog|earnings_article-606644 Nov 06, 2019 - Radius (RDUS) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019 as Tymlos gains traction.
Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales http://www.zacks.com/stock/news/610314/corcept-cort-earnings-beat-in-q3-korlym-boosts-sales?cid=CS-ZC-FT-analyst_blog|earnings_article-610314 Nov 08, 2019 - Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.
Top Research Reports for Merck, Eli Lilly & Charter Communications http://www.zacks.com/research-daily/643445/top-research-reports-for-merck-eli-lilly-charter-communications?cid=CS-ZC-FT-research_daily-643445 Nov 27, 2019 - Top Research Reports for Merck, Eli Lilly & Charter Communications
Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor http://www.zacks.com/stock/news/667111/lilly-initiates-phase-iii-lung-cancer-study-on-ret-inhibitor?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-667111 Dec 12, 2019 - Lilly (LLY) initiates a phase III study on its oral RET inhibitor, selpercatinib, in treatment-naive, RET fusion-positive NSCLC patients.
Pfizer's Braftovi sNDA Accepted by FDA for Priority Review http://www.zacks.com/stock/news/678304/pfizers-braftovi-snda-accepted-by-fda-for-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-678304 Dec 19, 2019 - FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy http://www.zacks.com/stock/news/685884/allergan-agn-gets-fda-approval-for-migraine-drug-ubrelvy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-685884 Dec 24, 2019 - Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.
A $20 Billion Sweet Spot in Biotech https://www.fool.com/investing/2019/12/28/a-20-billion-sweet-spot-in-biotech.aspx?source=iedfolrf0000001 Dec 28, 2019 - Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.

Pages: 12345

Page 1>